SCHEMBL907066

SCHEMBL907066

Cc1ccc(S(=O)(=O)CC(CS(=O)(=O)c2ccc(C)cc2)C(=O)c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.65
ALDH1A1 P00352 5/20 0.54
MAPT P10636 4/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
THRB P10828 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD11B1 P28845 1/20 0.49
ACHE P22303 2/20 0.49
HSD17B10 Q99714 1/20 0.49
KMT2A Q03164 5/20 0.48
CA9 Q16790 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12642017 0.89 ALDH1A1 (0.50) PKMALDH1A1MAPTLMNACYP1A2
SCHEMBL4505612 0.86 FLT1 (0.54) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL4528141 0.85 KMT2A (0.65) PKMALDH1A1MAPTLMNACYP1A2
SCHEMBL907263 0.83 CA12 (0.55) ALDH1A1MAPTLMNASMN1; SMN2HSD11B1
SCHEMBL21151897 0.83 ALDH1A1 (0.45) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL17688654 0.83 ALDH1A1 (0.48) PKMALDH1A1MAPTLMNACYP3A4
SCHEMBL13333146 0.83 MAPT (0.50) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL23280908 0.82 ALDH1A1 (0.44) PKMALDH1A1MAPTLMNACYP3A4
SCHEMBL17402095 0.82 KMT2A (0.46) PKMALDH1A1MAPTLMNACYP3A4
SCHEMBL21151875 0.82 ALDH1A1 (0.47) PKMALDH1A1MAPTLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2133099-B1 Conjugated biological molecules and their preparation POLYTHERICS LTD (GB) 2017-04-19 EP disclosed
US-9439974-B2 Conjugated biological molecules and their preparation POLYTHERICS LIMITED (GB) 2016-09-13 US disclosed
EP-2253330-B1 Conjugated biological molecules and their preparation POLYTHERICS LTD (GB) 2015-08-19 EP disclosed
EP-2277550-B1 Process for the preparation of conjugated biological molecules. POLYTHERICS LTD (GB) 2015-04-29 EP disclosed
US-20140369960-A1 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION ABZENA (CAMBRIDGE) LIMITED (GB) 2014-12-18 US disclosed
US-8816051-B2 Conjugated biological molecules and their preparation POLYTHERICS LIMITED (GB) 2014-08-26 US disclosed
US-20110182855-A1 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION POLYTHERICS LIMITED (GB) 2011-07-28 US disclosed
US-7939630-B2 Conjugated biological molecules and their preparation POLYTHERICS LIMITED (GB) 2011-05-10 US disclosed
EP-2277550-A1 Conjugated biological molecules and their preparation Polytherics Limited (GB) 2011-01-26 EP disclosed
EP-2253330-A2 Conjugated biological molecules and their preparation Polytherics Limited (GB) 2010-11-24 EP disclosed
EP-1893741-A1 CELL-BASED MICROARRAYS, AND METHODS FOR THEIR PREPARATION AND USE Beckman Coulter, Inc. (US) 2008-03-05 EP disclosed
WO-2007001817-A1 CELL-BASED MICROARRAYS, AND METHODS FOR THEIR PREPARATION AND USE BECKMAN COULTER, INC. (US) 2007-01-04 WO disclosed
US-20060292559-A1 Cell-based microarrays, and methods for their preparation and use BECKMAN COULTER, INC. (US) 2006-12-28 US disclosed
US-20060210526-A1 polyoxyethylene glycol-protein conjugate linked via linking group ABZENA (CAMBRIDGE) LIMITED (GB) 2006-09-21 US disclosed
EP-1648518-A2 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION Polytherics Limited (GB) 2006-04-26 EP disclosed
WO-2005007197-A2 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION POLYTHERICS LIMITED (GB) 2005-01-27 WO disclosed
US-5648213-A IMMUNOASSAY BECKMAN INSTRUMENTS, INC. (US) 1997-07-15 US disclosed
EP-0779934-A1 COMPOSITIONS AND METHODS FOR USE IN DETECTION OF ANALYTES BECKMAN INSTRUMENTS, INC. (US) 1997-06-25 EP disclosed
WO-1996006948-A1 COMPOSITIONS AND METHODS FOR USE IN DETECTION OF ANALYTES BECKMAN INSTRUMENTS, INC. (US) 1996-03-07 WO disclosed
EP-0562624-A2 Stabilization of functional proteins Modrovich, Ivan E. (US) 1993-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140369960-A1 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION F13B, F13A1, ZYX PKM 2366/4885ALDH1A1 3197/4885MAPT 4472/4885
US-20110182855-A1 CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION F13B, ZYX, F13A1 PKM 2623/4885ALDH1A1 3013/4885MAPT 4643/4885
US-20060210526-A1 polyoxyethylene glycol-protein conjugate linked via linking group F13A1, F13B, SSB PKM 3131/4885ALDH1A1 4140/4885MAPT 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.